We are live on
!
Find out more
Royalty Pharma
RPRX
RPRX
279 hedge funds and large institutions have $10.5B invested in Royalty Pharma in 2022 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 130 increasing their positions, 59 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
902% more call options, than puts
Call options by funds: $39.2M | Put options by funds: $3.92M
120% more repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 59
44% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 36
5% more funds holding
Funds holding: 266 → 279 (+13)
0.01% less ownership
Funds ownership: 62.46% → 62.46% (-0.01%)
1% less capital invested
Capital invested by funds: $10.7B → $10.5B (-$150M)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
Holders
279
Holders Change
+13
Holders Change %
+4.89%
% of All Funds
4.4%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.14%
New
52
Increased
130
Reduced
59
Closed
36
Calls
$39.2M
Puts
$3.92M
Net Calls
+$35.3M
Net Calls Change
-$2.61M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$241M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$87.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$61.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$53.8M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$44.3M |
